Bio-Rad Laboratories, Inc., GENERAL ELECTRIC and Agilent Technologies, Inc. are dominating the Global Prepacked Chromatography Columns Market in the year 2019

Global prepacked chromatography columns market is expected to reach USD 165,328.87 thousand by 2026 from USD 78,263.68 thousand in 2018, at a CAGR of 9.9% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below.

Access Full Report at

The prepacked chromatography columns market is a highly concentrated market which includes key players and local players. The market has witnessed increased strategic developments owing to favourable market scenario. The market has a prominent growth in upcoming years due to the demand of pharmaceutical and biotechnology, nutraceuticals food and beverage and analytical laboratory which is one of the factors boosting the growth of the market. The rising health issues population and its appropriate identification and treatment are growing tremendously. The health related issues is driving the prepacked column chromatography market due to high requirement of the biological tests and techniques and cost effective purification of biological drugs.

The market has witness developments in terms of merger and acquisitions or product launches to enhance the product portfolio in order to meet the rising demand of innovative technology. For instance, in January 2019, Shimadzu Corporation announced the launch of its Nexera Prep Series Preparative Purification Liquid Chromatograph (LC). It will help in the extraction of the target molecules in pharmaceutical analysis. It will help in improving the efficiency via effective preparative work using LC or an LCMS. It will help in adding the innovative and upgraded product which meets the demand of market and maintains the product standards of the company.

Bio-Rad Laboratories, Inc. dominated the global prepacked chromatography columns market and accounts for the highest market share in 2018 which is followed by GENERAL ELECTRIC and Agilent Technologies, Inc. The other key players existing in the market includes Thermo Fisher Scientific Inc., Repligen Corporation, Tosoh Corporation, Merck & Co., Inc., Phenomenex Inc., F. Hoffmann-La Roche Ltd and others.

Bio-Rad Laboratories, Inc.:

Bio-Rad Laboratories, Inc. headquartered in California, U.S. was founded in 1952. The company focusses on developing and manufacturing of life science and diagnostics products via analysing various chemical and biological products. The company has three operating divisions namely, life science research, clinical diagnostics and other operations.

Life science research segment offers advanced tools, reagents, apparatus and laboratory instruments which is used pharmaceutical and healthcare industry. Clinical diagnostics segment engaged in designing, manufacturing, selling and supporting informatics systems, test systems, test kits and specialized quality controls. The life science research segment recorded revenue of USD 861.70 million in 2018 and increased by 9.74% as compared to the revenue of USD 785.20 million generated in 2017, owing to growth due to price had an positive effect on accelerating the revenue of the biological materials and its rising demand of product for in genome, pharmaceutical and cellular biology and food safety.

In August 2018, Bio-Rad Laboratories, Inc. announced the launch of two chromatography samples for protein purification namely CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q. The new products are introduced to fulfil the demand of chromatography technology requirements regarding precision, safety and reproducibility.

It has its global networks in Europe, Pacific Rim, United States, Canada and Latin America. The company has various subsidiaries such as DiaMed Holding AG (Switzerland), Bio-Rad AbD Serotec Limited (U.K.), RainDance Technologies, Inc. (U.S.), QuantaLife, Inc. (U.S.), MorphoSys US, Inc. (U.S.) and others.


GENERAL ELECTRIC headquartered in Illinois, U.S. was founded in 1994. The company focusses on manufacturing biopharmaceuticals and providing medical technologies and data analytics decisions which help the healthcare professionals to monitor, diagnose and treat the patients. The company operates through two business segments which include industrial and financial services.

Industrial segment includes Oil & Gas, Aviation, Healthcare and Renewable Energy, Power, Lighting and Transportation. Financial services deals in product development cycles, research and development expenditures and regulatory standards. The industrial segment recorded revenue of USD 115,664 million in 2018 and a growth by 2.20% as compared to previous year owing to growth is driven by net effects of acquisitions of USD 5.5 billion, particularly attributable by Baker Hughes and also pharmaceutical and analytical products are experiencing high demand in the market.

In March 2019, GE Heathcare and Rockwell Automation collaborated their automation technologies and bioprocessing unit operations. This would help both the companies to meet the consumer demands in the markets and respond rapidly to market demands and adapt the manufacturing environment. GE Healthcare also mentioned that it would help them to provide innovative solutions towards the need of biopharma.

It has its global networks in the Asia-Pacific, Africa, Europe, North America and Latin America. It operates through its subsidiaries such as Biacore (Sweden), Dharmacon (U.S.), Hyclone Laboratories Inc. (U.S.), Biosafe SA (Switzerland), Nihon Medi-Physics Co.,Ltd. (Japan), Medi-Physics, Inc. (U.S.) and others.

Agilent Technologies, Inc.:

Agilent Technologies, Inc. company is headquartered in California, U.S. was founded in 1999. The company is engaged in providing instruments, services, consumables in life sciences, diagnostics and applied chemical markets. The company operates through three business segments which include Life Science & Applied Markets, Diagnostics & Genomics and Agilent CrossLab.

The life science & applied markets which is market focused segment mainly deals with liquid chromatography, mass spectrometry systems, gas mass spectrometry systems, inductively coupled plasma mass spectrometry systems, atomic absorption instruments, Raman spectroscopy, cell analysis plate based assays, flow cytometry and others. Diagnostics and genomics business offers pathology, companion diagnostics, reagent partnership, genomics, nucleic acid contract manufacturing, research and development and biomolecular analysis businesses. Agilent CrossLab business includes extensive consumables and services portfolio such as sample preparation products, GC and LC columns and other laboratory instrument supplies. The life science & applied markets segment generated revenue of USD 2,270 million in 2018 and has witnessed growth by 9.08% as compared to the revenue of USD 2,081 million generated in 2017. The growth is because of the rising demand in the healthcare industry for the analysis and carrying out the pharmaceutical experiments.

In February 2018, Agilent Technologies Inc. launched two new gas chromatography systems that will initiate innovative and intelligent self-aware predictive technology and also help in expanding their portfolio of GC instruments. It will also help the customers by expanding their system intelligent functions.

The company has its global networks through direct sales representatives and distributors in Americas, Asia-Pacific and Europe. It operates through its subsidiaries such as Advanced Analytical Technologies, Inc. (U.S.), ACEA BIO (U.S.), Genohm (Switzerland), Multiplicom N.V. (U.S.), Cobalt Light Systems (U.S.), Seahorse Bioscience (U.S.).